GEHC · CIK 0001932393
What GE HealthCare Technologies Inc. told the SEC could break it.
GE HealthCare's disclosures cluster on critical-input dependence, trade policy and the heavy regulation of its markets — with China running through much of it. Its manufacturing relies on volatile raw materials including helium, iodine and rare earth minerals, and China's 2025 tightening of rare-earth export controls (only partly and temporarily eased after October 2025 trade talks) could constrain production and margins, while incremental tariffs already contributed to cost inflation that cut Imaging segment EBIT by $71 million. Its device and pharmaceutical products are subject to stringent regulation across its three largest revenue regions — the U.S. FDA, the EU and China's NMPA — and China's volume-based procurement and reimbursement-list policies can limit its access to public-hospital sales.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- tariffs (quantified hit to Imaging and AVS segment EBIT)medium
Incremental tariffs contributed to cost inflation that measurably reduced GE HealthCare's segment EBIT in 2025 — Imaging EBIT fell $71M (cost inflation incl. incremental tariffs) and AVS faced the same headwind — with further tariff/trade-environment risk to customer purchasing and costs.
“For the year ended December 31, 2025 Imaging Segment EBIT was $891 million, a decrease of $71 million due to cost inflation, including the impact of incremental tariffs, partially offset by a growth in sales volume, an increase in price, and cost productivity; AVS Segment EBIT was $1,175 million, an increase of $58 million due to growth in sales volume and cost productivity, partially offset by cost inflation, including the impact of incremental tariffs;”
- medical device and pharmaceutical regulation (FDA, EMA, NMPA)medium
GE HealthCare's device and pharmaceutical products are subject to stringent global regulation — FDA (U.S.), EMA/National Competent Authorities/Notified Bodies (EU), and NMPA (China) — across its three most significant revenue regions, requiring extensive compliance resources.
“The development, manufacturing, marketing, sale, promotion, and distribution of medical devices and pharmaceutical products are subject to stringent government regulation globally. We commit extensive resources to maintain compliance with these regulations. The U.S., European Union (“EU”), and China are our most significant regions based on revenue and the regulatory landscape within these regions.”
Commodity & input dependence
- helium, iodine, and rare earth minerals (China rare-earth export controls)high
GE HealthCare depends on volatile raw materials — helium, iodine, and rare earth minerals; China significantly tightened rare-earth export controls in 2025 (only partly/temporarily suspended after October 2025 U.S. trade talks), and further restriction or price increases could constrain manufacturing and cut margins.
“We rely upon supplies of certain raw materials, including helium, iodine, and rare earth minerals. Worldwide demand, availability, export restrictions, and pricing of these raw materials have been volatile, and we expect that to continue in the future. For example, in 2025, China significantly tightened its export controls on rare earth minerals. Some, but not all, of these restrictions were temporarily suspended after trade negotiations with the U.S. in October 2025.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“We employ direct purchase or finance arrangements with such firms as GE, Hologic, Key Equipment, Philips, Siemens and Spectrum for our diagnostic equipment imaging needs.”
Cited →
Its suppliers
“Our top five customers, measured by revenue, are Canon Medical Systems Corporation ("Canon"), United Imaging Healthcare, General Electric Company, Siemens Healthineers AG ("Siemens"), and Rapiscan Systems, Inc., which collectively accounted for approximately 40% of total revenue in fiscal year 2025.”
Cited →“In September 2024, GE Healthcare announced that it had received FDA approval of flurpiridaz under the name Flyrcado for coronary artery disease diagnosis and confirmed launch and availability of Flyrcado in April 2025.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch